Cargando…
The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19
Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and pre-clinical data suggest alpha-1 adrenergic receptor antagonists (α(1)-AR antagonists) may be effective in reducing mortality related to hyperinflammation independent of etiology. Using a retrospective cohort desig...
Autores principales: | Rose, Liam, Graham, Laura, Koenecke, Allison, Powell, Michael, Xiong, Ruoxuan, Shen, Zhu, Mench, Brett, Kinzler, Kenneth W., Bettegowda, Chetan, Vogelstein, Bert, Athey, Susan, Vogelstein, Joshua T., Konig, Maximilian F., Wagner, Todd H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048524/ https://www.ncbi.nlm.nih.gov/pubmed/33869251 http://dx.doi.org/10.3389/fmed.2021.637647 |
Ejemplares similares
-
The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19
por: Rose, Liam, et al.
Publicado: (2021) -
Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection
por: Koenecke, Allison, et al.
Publicado: (2021) -
Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study
por: Powell, Michael, et al.
Publicado: (2021) -
Association of α1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark
por: Thomsen, Reimar W., et al.
Publicado: (2021) -
Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients
por: Li, Shilong, et al.
Publicado: (2022)